UVB-Induced MVP Release in Human Skin (NCT05734235) | Clinical Trial Compass
CompletedPhase 1
UVB-Induced MVP Release in Human Skin
United States8 participantsStarted 2018-07-16
Plain-language summary
This study is designed to assess if ultraviolet B radiation (UVB) found in sunlight causes the release of microvesicle particles in human skin, and if antioxidant vitamins can block their production.
Who can participate
Age range21 Years – 45 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male subjects
* Ages 21 to 45
* Skin type: Fitzpatrick Type I or II
Exclusion Criteria:
* Have underlying diseases that could affect wound healing
* On medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS \[except for low-dose aspirin\] or steroids)
* History of abnormal scarring (e.g., keloids)
* Should not be on Vitamin C or E supplements for past month
* Unable to understand/complete informed consent
* Large volar arm tattoos that would inhibit the ability to conduct/evaluate the skin testing
* Renal compromise/kidney stones or allergy to Vitamin C/Vitamin E or lidocaine anaesthetic
* Use of tanning bends or recent UVB exposure to the areas in the past 3 months
* Recent (within 1 week) use to sunscreen to volar forearms
What they're measuring
1
Change in microvesicle particles (MVP) levels from baseline